Mode
Text Size
Log in / Sign up

Spinal cord stimulation with medical management reduces pain intensity in painful diabetic neuropathySpinal Cord Stimulation Shows Promise for Diabetic Neuropathy Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider spinal cord stimulation as a potential adjunct to medical management for patients with refractory painful diabetic neuropathy.

This meta-analysis evaluates the efficacy of spinal cord stimulation (SCS) combined with conventional medical management compared to medical management alone for adults with painful diabetic neuropathy (PDN). The analysis indicates that patients receiving SCS and medical management experienced significant improvements in pain intensity, with a mean difference of 4.09 (95% CI 2.58-5.59; p < 0.001). Additionally, a higher proportion of patients achieved at least 50% pain relief (RR 0.11; p < 0.001) and showed significant improvements in quality of life (MD -0.17; p < 0.001).

Regarding secondary outcomes, the study found no statistically significant differences between the groups in terms of sleep quality (p > 0.05) or complication rates (p > 0.05). The authors note that while SCS may have a potential role as an adjunct for refractory PDN, several limitations exist. Specifically, more trials are required to clarify long-term neurological outcomes, limb-related outcomes, and real-world effectiveness.

Clinically, these findings suggest that SCS may be a viable option for patients with refractory pain who do not respond sufficiently to standard medical therapies. However, the lack of data on long-term durability and specific limb-related impacts means its role in routine practice should be applied cautiously.

How this fits prior evidence

This meta-analysis addresses the management of diabetic neuropathy, which is a comprehensive disorder affecting peripheral, autonomic, and central nervous systems. While previous evidence highlights the high prevalence of complications among adults with diabetes, this study specifically evaluates an intervention for pain intensity in those with painful diabetic neuropathy. The finding that SCS reduces pain intensity provides a specific management option for the nerve damage caused by chronic hyperglycemia.

Researchers analyzed data regarding the use of spinal cord stimulation (SCS) combined with standard medical management for adults suffering from painful diabetic neuropathy. This condition often causes significant discomfort and can impact daily life.

The analysis found that patients who received both SCS and conventional care experienced significant improvements in pain intensity compared to those receiving only standard treatment. Additionally, a higher proportion of patients using the combination therapy achieved at least 50% relief from their pain. While quality of life scores also showed improvement, there were no significant differences reported regarding sleep quality or complication rates.

Because this is a meta-analysis of existing data, it provides a broad look at current evidence but does not replace individual clinical judgment. More research is still needed to understand long-term effects on nerves and limbs, as well as how the treatment works in everyday real-world settings. Patients should discuss these findings with their healthcare provider to see if this approach fits their specific needs.

What this means for you:
Spinal cord stimulation combined with standard care may help reduce pain for adults with diabetic neuropathy.

Common questions

Does spinal cord stimulation help with the pain of diabetic neuropathy?

The study found that combining spinal cord stimulation (SCS) with standard medical management led to significant improvements in pain intensity for adults. A higher proportion of patients using this combined approach achieved at least 50% relief from their pain compared to those receiving only conventional treatment.

Are there safety concerns or complications with spinal cord stimulation?

The analysis reported no statistically significant differences in complication rates between those receiving spinal cord stimulation and those receiving standard care alone. While the treatment showed promise for pain reduction, more research is needed to understand long-term neurological outcomes.

Does this treatment improve sleep or quality of life?

The study found significant improvements in quality of life scores for patients using spinal cord stimulation combined with standard care. However, the data did not show any statistically significant differences regarding sleep quality between the two groups.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
OBJECTIVES: This study aimed to evaluate whether spinal cord stimulation (SCS) improves pain and patient-centered outcomes compared with conventional medical management in adults with painful diabetic neuropathy (PDN), and to synthesize evidence from randomized controlled trials (RCTs) regarding efficacy and safety. MATERIALS AND METHODS: A systematic search of PubMed, Scopus, Cochrane Library, Embase, and Google Scholar was conducted from inception through December 2025. Eligible studies were RCTs enrolling adults with diabetes and PDN that compared SCS combined with conventional medical management with conventional medical management alone. Outcomes included pain intensity, ≥ 50% pain relief, quality of life (QOL), sleep quality, and complications. Data were pooled using Review Manager 5.4. Mean differences (MD) were used for continuous outcomes and risk ratios (RR) for dichotomous outcomes, each with 95% confidence intervals (CIs). Random-effects models were used for the primary analyses, given the anticipated clinical and methodological heterogeneity across studies. RESULTS: Seven RCTs were included in the qualitative synthesis and 3 RCTs were included in the quantitative synthesis. Compared with conventional therapy alone, SCS was associated with significant improvements in pain intensity (MD 4.09, 95% CI 2.58-5.59; p < 0.001) and QOL (MD -0.17; p < 0.001). A higher proportion of patients achieved pain relief (RR 0.11; p < 0.001), favoring SCS. No statistically significant differences were observed in sleep quality or complication rates between groups (p > 0.05). CONCLUSIONS: In adults with refractory PDN, SCS was associated with clinically meaningful improvements in pain and QOL without an observed increase in adverse events. These findings suggest a potential role of SCS as an adjunct to conventional medical management, while further trials are needed to clarify long-term neurological, limb-related, and realworld effectiveness outcomes.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.